Liver Transplantation: Challenging Controversies and TopicsGregory T. Everson, James F. Trotter Liver Transplantation: Challenging Controversies and Topics grew out of a need I perceived within the fields of transplant hepatology and liver transplantation. Liver transplantation has rightly gained recognition as an established therapy for end-stage liver disease. Few would argue that liver transplantation is one of the few truly lifesaving and life-altering treatments within medicine and surgery. Not many realize that 20 years passed from the time of the first human liver transplantation in 1963 to its acceptance as therapy by the 1983 NIH Consensus Conference on Liver Transplantation. In 2008, 25 years will have passed since the 1983 NIH conference—a mere 25 years for a field that has provided patients hope, doctors options, and to some the “gift of life. ” Many issues in liver transplantation involve indications, patient selection, and outcomes after transplantation—these are standard topics, covered by textbooks of hepatology and transplantation. In contrast, the field of liver tra- plantation is young, evolving, dynamic, and issues and decisions are often controversial. Thus, Dr. Trotter and I, as well as our colleagues at the University of Colorado, felt that a text with a different focus was required, one that highlighted controversy and challenged dogma. Out of this perceived need emerged Liver Transplantation: Challenging Controversies and Topics. To meet the transplant community’s need for emerging information about liver transplantation, Dr. Larry Chan, Dr. Igal Kam, and I initiated the Controversies in Transplantation Conference. |
Contents
1 | |
19 | |
3 Pre and Posttransplant Management of Hepatitis C | 45 |
4 The Dilemma of AdulttoAdult Living Donor Liver Transplantation | 65 |
5 The Share 15 Rule | 91 |
6 Hepatocellular Carcinoma | 103 |
7 Liver Transplantation and the Hepatopulmonary Syndrome | 123 |
8 LongTerm Metabolic Complications Posttransplantation | 135 |
9 Hepatitis B and Liver Transplantation | 145 |
10 Liver Transplantation for Nonalcoholic Fatty Liver Disease | 169 |
Index | 191 |
Other editions - View all
Liver Transplantation: Challenging Controversies and Topics Gregory T. Everson,James F. Trotter No preview available - 2011 |
Liver Transplantation: Challenging Controversies and Topics Gregory T. Everson,James F. Trotter No preview available - 2008 |
Liver Transplantation: Challenging Controversies and Topics Gregory T. Everson,James F. Trotter No preview available - 2010 |
Common terms and phrases
acute rejection Adefovir adult adult-to-adult living donor aLDLT allocation allograft Ann Surg antibody antigen associated basiliximab biliary candidates cells centers chronic hepatitis cirrhosis Clin clinical complications cyclosporine daclizumab deceased donor diabetes mellitus donor liver transplantation dose dyslipidemia effects end-stage liver disease fibrosis Gastroenterology graft HBIg HCV infection hepatitis C virus hepatocellular carcinoma Hepatol Hepatology hepatopulmonary syndrome histological hypertension hypoxemia immunosuppression impact improve incidence increased insulin resistance interferon lamivudine liver recipients liver trans Liver Transpl 2004 liver transplant recipients living donor liver long-term LSECs MELD score metabolic Milan criteria monotherapy mortality multicenter NAFLD NASH nonalcoholic obesity organ orthotopic liver transplantation outcome patients with HCC post-OLT posttransplant posttransplantation prophylaxis rapamycin receptor recurrent HCV recurrent hepatitis regimens renal reported ribavirin right lobe allografts sirolimus steatohepatitis steatosis steroids survival tacrolimus tion tolerance Transpl Proc transplantation for hepatocellular treatment tumor vascular viral